fbpx

Illumina’s Antitrust Battles To End With Divestiture Of Cancer Test Maker Grail

Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024.

The post Illumina’s Antitrust Battles To End With Divestiture Of Cancer Test Maker Grail appeared first on Above the Law.

Related Articles

Responses

Your email address will not be published. Required fields are marked *